Table 5.6i

Immunosuppression Use for Antirejection Treatment from Transplant

to One Year Following Transplantation, 1995 to 2004

Recipients with Kidney Transplants

  Year of Transplant
1995 1996 1997 1998 1999 2000 2001 2002 2003 2004
Transplants 11,081 11,397 11,701 12,451 12,758 13,611 14,265 14,778 15,136 16,004
Tx with Antirejection Treatments 4,317 5,832 3,442 2,653 2,447 2,379 2,394 2,191 1,995 1,844
Antibodies Any in Category 32.1% 16.8% 27.2% 37.0% 37.1% 35.6% 37.6% 38.5% 47.7% 48.1%
ALG 5.8% 0.3% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Atgam/NRATG/NRATS 2.3% 3.4% 6.6% 8.1% 6.0% 2.9% 2.5% 2.3% 1.8% 1.1%
OKT3 26.5% 13.9% 21.6% 26.3% 18.8% 14.6% 11.7% 10.8% 8.9% 7.7%
Thymoglobulin 0.0% 0.1% 0.2% 1.0% 7.9% 13.0% 18.1% 23.6% 31.2% 33.1%
Zenapax 0.0% 0.0% 0.2% 3.4% 5.8% 3.4% 2.9% 1.9% 3.1% 3.4%
Simulect 0.0% 0.0% 0.0% 0.3% 1.6% 4.0% 5.0% 3.3% 5.5% 4.9%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.2% 1.4% 1.5%
Corticosteroids Any in Category 58.0% 38.5% 58.7% 78.7% 78.4% 80.1% 80.2% 79.7% 72.4% 70.5%
Steroids 58.0% 38.5% 58.7% 78.7% 78.4% 80.1% 80.2% 79.7% 72.4% 70.5%
Antimetabolites Any in Category 0.2% 0.3% 0.5% 0.1% 0.1% 0.3% 0.2% 0.1% 0.2% 0.5%
Cytoxan 0.1% 0.2% 0.3% 0.1% 0.1% 0.3% 0.1% 0.1% 0.2% 0.4%
Methotrexate 0.1% 0.1% 0.2% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1%


Source: OPTN/SRTR Data as of May 1, 2006.

Individual drug percentages will not necessarily add up to the drug category percentages, as patients maybe prescribed more than one drug within the same category.